Biotech Values

[DewDiligence]

INCY, AZN collaborate (non-exclusively) on immuno-oncology clinical trials:

http://finance.yahoo.com/news/incyte-medimmune-announce-collaboration-immuno-060000126.html

Incyte Corporation and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into a clinical study collaboration. The Phase I/II oncology study will evaluate the efficacy and safety of MedImmune’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.

…MedImmune and Incyte will collaborate on a non-exclusive basis on the study, to evaluate the combination in multiple solid tumors including metastatic melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck and pancreatic cancer.

The Phase I part of the trial is expected to establish a recommended dose regimen of both MEDI4736 and INCB24360 and the Phase II part of the study will assess the safety and efficacy of the combination… The study will be co-funded equally by Incyte and MedImmune and conducted by Incyte.